A. Nougairede

In vivo rescue of arboviruses directly from subgenomic DNA fragments

The paper demonstrates an in vivo method to generate arboviruses from subgenomic DNA fragments, achieving 100% infection rate in mice with optimized electroporation parameters.

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

The paper generates and evaluates SARS-CoV-2 mutants resistant to protease inhibitors nirmatrelvir and ensitrelvir, showing in vitro and in vivo resistance and linking M49L mutation prevalence to Xocova(R) use.

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model

This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model

This study evaluates Sotrovimab's antiviral activity against BQ.1.1 and XBB.1 Omicron variants in a hamster model, finding retained but reduced efficacy compared to earlier variants.

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant

This study shows niclosamide is effective against SARS-CoV-2 and its variants in a human airway model, supporting its potential as a COVID-19 therapy.

Alpha variant versus D614G strain in the Syrian hamster model

This study compares the SARS-CoV-2 Alpha variant and G614 strain in Syrian hamsters, finding similar replication and disease outcomes but a slight fitness advantage for G614.

Replicative fitness SARS-CoV-2 20I/501Y.V1 variant in a human reconstituted bronchial epithelium

This study compares the replication efficiency of the SARS-CoV-2 20I/501Y.V1 variant with an ancestral strain in human bronchial epithelium models, finding the variant outcompetes the ancestral strain in competition experiments.

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

This study screens an FDA-approved chemical library to identify potential inhibitors of SARS-CoV-2 replication in vitro, finding several compounds with antiviral potency.

An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice

This paper identifies an E460D substitution in TBEV RdRp that confers resistance to Galidesivir and attenuates the virus in mice.

Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone

This paper develops a chimeric Zika virus vaccine using a yellow fever 17-D backbone and shows it induces neutralizing antibodies and protects mice against ZIKV challenge.